Company Overview
About Muna Therapeutics
Muna Therapeutics focuses on microglial biology — the specialized immune cells of the brain — as the key to developing disease-modifying Alzheimer's therapies beyond amyloid targeting. The company uses induced pluripotent stem cell (iPSC)-derived microglia as disease models to identify and validate novel drug targets implicated by Alzheimer's genetics (TREM2, PLCG2, BIN1, APOE). This platform enables the company to study microglial dysfunction at scale and run drug screens against human-relevant cellular models.
Business Model & Competitive Advantage
Founded in Copenhagen in 2020 with co-founders from the UK Dementia Research Institute, Muna raised $75M in 2024 and is advancing multiple small molecule and antibody programs targeting TREM2 agonism and related microglial activation pathways. The company's approach differs from antibody-based TREM2 programs (Alector, Vigil Neuroscience) by pursuing oral small molecules that can penetrate the blood-brain barrier.
Competitive Landscape 2025–2026
With Alzheimer's affecting 55 million people worldwide and limited options beyond recently approved anti-amyloid antibodies, microglial biology represents one of the most genetics-validated unexplored therapeutic avenues. Muna's iPSC platform advantage enables rapid target validation cycles that outpace traditional neuroscience drug discovery timelines.
Open Positions
Reddit Discussions
Key Differentiators
Emerging Innovator
Muna Therapeutics is an emerging player bringing innovative solutions to the BioTech market.
Frequently Asked Questions
Not So Random Others
a2z Radiology AI
a2z Radiology AI has developed a whole-body CT analysis platform that simultaneously screens for over 24 medical conditions across a single CT scan, including incidental cancers, coronary artery disea
Adept AI
Adept AI was founded in 2022 by a team of former OpenAI, DeepMind, and Google Brain researchers to build AI that can take actions on computers — navigating software interfaces, filling forms, and exec
Plenty
Plenty is a San Francisco-based indoor vertical farming company that uses AI, machine learning, and robotics to grow leafy greens and other produce in controlled indoor environments. The company has r
80 Acres Farms
80 Acres Farms is a commercial-scale indoor vertical farming company that, following its merger with Soli Organic, operates the largest indoor farming network in North America. The company raised $115
Duckie
Duckie is a San Francisco-based AI customer support platform — backed by Y Combinator (W24) with $500,000 in funding from Y Combinator, Andreessen Horowitz, Greylock, KungHo Fund, Netflix, and 5 addit
Honda
Honda Motor Co., Ltd. is a Japanese multinational mobility conglomerate founded in 1948 by Soichiro Honda and Takeo Fujisawa in Hamamatsu, Japan. Starting as a motorcycle manufacturer, Honda expanded
Compare Muna Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Muna Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Muna Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Muna Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →